Fluoride: Page 54

4th Merck osteonecrosis trial begins

By DrBicuspid.com staff writers

Merck will again "vigorously defend itself" against allegations that its Fosamax bisphosphonate drug caused dental and jaw-related problems in a jury trial that began January 18 in New Jersey.

January 17, 2011

FDA limits acetaminophen in combination products

By DrBicuspid.com staff writers

The U.S. Food and Drug Administration (FDA) is asking manufacturers of prescription combination products that contain acetaminophen to limit the amount of acetaminophen to no more than 325 milligrams in each tablet or capsule.

January 12, 2011

Moxifloxacin beats clindamycin for some odontogenic infections

By Reuters Health

NEW YORK (Reuters Health) - Moxifloxacin was significantly more effective than clindamycin at controlling the pain of odontogenic/gingival inflammatory infiltrates, in a small phase II study by German researchers.

January 9, 2011

Head/neck cancer drug shows promise in clinical trials

By DrBicuspid.com staff writers

CEL-SCI has begun a phase III clinical trial for Multikine, its flagship immunotherapy drug for head and neck cancer. The goal is to establish Multikine as a first-line standard of care therapy in treating newly diagnosed head and neck cancer patients.

January 5, 2011

Private equity firm acquires OraPharma

By Kathy Kincade

Water Street Healthcare Partners, a strategic private equity firm, has acquired OraPharma from Johnson & Johnson and plans to build it into a leading specialty pharmaceutical company focused on dental and oral healthcare.

January 4, 2011

Zometa aids patients with head and neck cancer

By DrBicuspid.com staff writers

The bisphosphonate Zometa appears to reduce bone loss and decrease tumor size in patients with head and neck cancer, according to a study in Cancer Research.

December 12, 2010